Satiety Response of Short Chain Fructooligosaccharide

University of Minnesota (UMN)

Status and phase: Completed; Early Phase 1

Conditions: Healthy

Treatments: Dietary Supplement: Short chain fructooligosaccharide (scFOS) 8 g; Other: Placebo; Dietary Supplement: Short chain fructo-oligosaccharide (scFOS) 5 g

Study type: Interventional

Funder types: Other

Identifiers

NCT01100788

0806M37444

Details and patient eligibility

About

Populations that report high fiber consumption demonstrate lower rates of obesity. Enhanced satiety may play a key role in this relationship. The colonic fermentation of fibers is theorized to influence satiety and food intake. Short chain fructooligosaccharide (scFOS) are rapidly fermentable fibers that can easily be added to foods to impact these parameters.

The objective of this study was to evaluate the satiety response of scFOS and its ability to decrease food intake.

Full description

Intervention study with fiber added to beverages and acute effects on satiety measured.

Enrollment: 20 patients

Sex: All

Ages: 18 to 64 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy men and women
• Age 18-64 years
• Non-smoking
• Not taking medication
• Non-dieting (weight stable in prior 3 months)
• BMI 18-27
• English literacy

Exclusion criteria

• Do not regularly consume breakfast
• Food allergies to ingredients found in study products
• BMI <18 or >27
• Diagnosed cardiovascular, renal, or hepatic disease diabetes mellitus
• Cancer in previous 5 years (except basal cell carcinoma of the skin)
• Any gastrointestinal disease or condition
• Recent bacterial infection (< 3 months)
• Recent or concurrent participation in an intervention research study
• History of drug or alcohol abuse in prior 6 months
• Use of lipid-lowering, anti-hypertensive, or anti-inflammatory steroid medication
• Eating disorder
• Vegetarians
• People who eat more than approximately 15 grams of fiber per day
• Women who are pregnant or lactating
• Women with irregular menstrual cycles

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

20 participants in 3 patient groups, including a placebo group

Placebo

Placebo Comparator group

Description:

No treatment

Treatment:

Other: Placebo

scFOS 5 g

Experimental group

Description:

5 g scFOS

Treatment:

Dietary Supplement: Short chain fructo-oligosaccharide (scFOS) 5 g

scFOS 8 g

Experimental group

Description:

8 g scFOS

Treatment:

Dietary Supplement: Short chain fructooligosaccharide (scFOS) 8 g